Skip to content
drillr.ai
Sign up

BCLI

Brainstorm Cell Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.05
−1.87%
Ask drillr

  • Aug 14, 2026, 20:00 UTC

    BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update on its NurOwn ALS program preparations for the Phase 3b ENDURANCE study.

    Source:

  • Aug 4, 2026, 19:28 UTC

    Lunai Bioworks signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027.

    Source: